Skip to main content

Advertisement

SpringerLink
Log in

Of Mesenchymal Stem/Stromal Cells and Osteoarthritis: Time to Merge the Latest Breakthroughs

  • Published:
Stem Cell Reviews and Reports Aims and scope Submit manuscript

Abstract

Osteoarthritis (OA) is a degenerative joint disease of the articular cartilage with subchondral bone remodeling and synovial inflammation. There is currently no cure for OA, making effective management extremely challenging. During the last years, significant advances has been made to develop regenerative medicine based on the use of stem cells as alternative for treating OA. Because of their several advantages including availability, expandability, transplantability, and ethical implications. mesenchymal stem/stromal cells (MSCs) appear thus to be a promising tool for the field. Based on the recent paper of Klemen Čamernik et al. in Stem Cell Reviews and Reports, we highlighted some challenges and possible strategies to enhance the therapeutic potential of MSCs for OA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Čamernik, K., Mihelič, A., Mihalič, R., Marolt Presen, D., Janež, A., Trebše, R., Marc, J., & Zupan, J. (2020). Increased Exhaustion of the Subchondral Bone-Derived Mesenchymal Stem/ Stromal Cells in Primary Versus Dysplastic Osteoarthritis [published online ahead of print, 2020 Mar 21]. Stem Cell Reviews and Reports.

  2. Litwic, A., Edwards, M. H., Dennison, E. M., & Cooper, C. (2013). Epidemiology and burden of osteoarthritis. British Medical Bulletin, 105, 185–199.

    Article  Google Scholar 

  3. Harrell, C. R., Markovic, B. S., Fellabaum, C., Arsenijevic, A., & Volarevic, V. (2019). Mesenchymal stem cell-based therapy of osteoarthritis: Current knowledge and future perspectives. Biomedicine & Pharmacotherapy, 109, 2318–2326.

    Article  CAS  Google Scholar 

  4. Berenbaum, F. (2013). Osteoarthritis as an inflammatory disease (osteoarthritis is not osteoarthrosis!). Osteoarthritis Cartilage, 21(1), 16–21.

    Article  CAS  Google Scholar 

  5. Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., & Santoro, A. (2018). Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nature Reviews Endocrinology, 14(10), 576–590.

    Article  CAS  Google Scholar 

  6. Hunter, D. J., & Bierma-Zeinstra, S. (2019). Osteoarthritis. Lancet, 393(10182), 1745–1759.

    Article  CAS  Google Scholar 

  7. Han, Y. H., Kim, K. H., Abdi, S., & Kim, T. K. (2019). Stem cell therapy in pain medicine. Korean Journal of Pain, 32(4), 245–255.

    Article  CAS  Google Scholar 

  8. Davies, R. L., & Kuiper, N. J. (2019). Regenerative medicine: A review of the evolution of autologous chondrocyte implantation (ACI) therapy. Bioengineering (Basel), 6(1), 22.

    Article  CAS  Google Scholar 

  9. Wang, A. T., Feng, Y., Jia, H. H., Zhao, M., & Yu, H. (2019). Application of mesenchymal stem cell therapy for the treatment of osteoarthritis of the knee: A concise review. World Journal of Stem Cells, 11(4), 222–235.

    Article  Google Scholar 

  10. Mancuso, P., Raman, S., Glynn, A., Barry, F., & Murphy, J. M. (2019). Mesenchymal stem cell therapy for osteoarthritis: The critical role of the cell secretome. Frontiers in Bioengineering and Biotechnology, 7, 9.

    Article  Google Scholar 

  11. Zhou, B. O., Yue, R., Murphy, M. M., Peyer, J. G., & Morrison, S. J. (2014). Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell, 15(2), 154–168.

    Article  CAS  Google Scholar 

  12. Čamernik, K., Mihelič, A., Mihalič, R., Haring, G., Herman, S., Marolt Presen, D., et al. (2020). Comprehensive analysis of skeletal muscle- and bone-derived mesenchymal stem/stromal cells in patients with osteoarthritis and femoral neck fracture. Stem Cell Research & Therapy, 11(1), 146.

    Article  Google Scholar 

  13. Sui, B. D., Hu, C. H., Zheng, C. X., & Jin, Y. (2016). Microenvironmental views on mesenchymal stem cell differentiation in aging. Journal of Dental Research, 95(12), 1333–1340.

    Article  CAS  Google Scholar 

  14. Mansilla, E., Díaz Aquino, V., Zambón, D., Marin, G. H., Mártire, K., Roque, G., et al. (2011). Could metabolic syndrome, lipodystrophy, and aging be mesenchymal stem cell exhaustion syndromes? Stem Cells International, 2011, 943216.

    Article  Google Scholar 

  15. Najar, M., Bouhtit, F., Melki, R., Afif, H., Hamal, A., Fahmi, H., et al. (2019). Mesenchymal stromal cell-based therapy: New perspectives and challenges. Journal of Clinical Medicine, 8(5), 626.

    Article  CAS  Google Scholar 

  16. Ishihara, T., Yoshida, M., & Arita, M. (2019). Omega-3 fatty acid-derived mediators that control inflammation and tissue homeostasis. International Immunology, 31(9), 559–567.

    Article  CAS  Google Scholar 

  17. Serhan, C. N., & Levy, B. D. (2018). Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. Journal of Clinical Investigation, 128(7), 2657–2669.

    Article  Google Scholar 

  18. Benabdoune, H., Rondon, E. P., Shi, Q., Fernandes, J., Ranger, P., Fahmi, H., & Benderdour, M. (2016). The role of resolvin D1 in the regulation of inflammatory and catabolic mediators in osteoarthritis. Inflammation Research, 65(8), 635–645.

    Article  CAS  Google Scholar 

  19. Cianci, E., Recchiuti, A., Trubiani, O., Diomede, F., Marchisio, M., Miscia, S., et al. (2016). Human periodontal stem cells release specialized proresolving mediators and carry immunomodulatory and prohealing properties regulated by Lipoxins. Stem Cells Translational Medicine, 5(1), 20–32.

    Article  CAS  Google Scholar 

  20. Silva, J. D., Lopes-Pacheco, M., de Castro, L. L., Kitoko, J. Z., Trivelin, S. A., Amorim, N. R., et al. (2019). Eicosapentaenoic acid potentiates the therapeutic effects of adipose tissue-derived mesenchymal stromal cells on lung and distal organ injury in experimental sepsis. Stem Cell Research & Therapy, 10(1), 264.

    Article  Google Scholar 

  21. Abreu, S. C., Lopes-Pacheco, M., da Silva, A. L., Xisto, D. G., de Oliveira, T. B., Kitoko, J. Z., et al. (2018). Eicosapentaenoic acid enhances the effects of mesenchymal stromal cell therapy in experimental allergic asthma. Frontiers in Immunology, 9, 1147.

    Article  Google Scholar 

  22. Najar, M., Ouhaddi, Y., Paré, F., Lussier, B., Urade, Y., Kapoor, M., Pelletier, J. P., Martel-Pelletier, J., Benderdour, M., & Fahmi, H. (2020). Role of Lipocalin-type prostaglandin D synthase in experimental osteoarthritis [published online ahead of print, 2020 Apr 26]. Arthritis & Rheumatology, 2020. https://doi.org/10.1002/art.41297.

  23. Verma, P., & Dalal, K. (2011). ADAMTS-4 and ADAMTS-5: key enzymes in osteoarthritis. Journal of Cellular Biochemistry, 112(12), 3507–3514.

    Article  CAS  Google Scholar 

  24. Li, H., Wang, D., Yuan, Y., & Min, J. (2017). New insights on the MMP-13 regulatory network in the pathogenesis of early osteoarthritis. Arthritis Research & Therapy, 19(1), 248.

    Article  Google Scholar 

  25. Lange, C., Brunswig-Spickenheier, B., Eissing, L., & Scheja, L. (2012). Platelet lysate suppresses the expression of lipocalin-type prostaglandin D2 synthase that positively controls adipogenic differentiation of human mesenchymal stromal cells. Experimental Cell Research, 318(18), 2284–2296.

    Article  CAS  Google Scholar 

  26. Vitale, S. G., Laganà, A. S., Nigro, A., La Rosa, V. L., Rossetti, P., Rapisarda, A. M., La Vignera, S., Condorelli, R. A., Corrado, F., Buscema, M., D’Anna, R. (2016) Peroxisome proliferator-activated receptor modulation during metabolic diseases and cancers: master and minions. PPAR Research, 2016, 6517313.

Download references

Funding

This study was supported by “La Chaire en Arthrose de l’Université de Montréal”, the Canadian Institutes of Health Research (Grant MOP-130293).

Author information

Authors and Affiliations

  1. Osteoarthritis Research Unit, University of Montreal Hospital Research Center (CRCHUM), Montreal, Quebec, H2X 0A9, Canada

    Mehdi Najar & Hassan Fahmi

Authors
  1. Mehdi Najar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hassan Fahmi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hassan Fahmi.

Ethics declarations

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Mehdi Najar and Hassan Fahmi are co-senior authors.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Najar, M., Fahmi, H. Of Mesenchymal Stem/Stromal Cells and Osteoarthritis: Time to Merge the Latest Breakthroughs. Stem Cell Rev and Rep 16, 1016–1018 (2020). https://doi.org/10.1007/s12015-020-10001-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12015-020-10001-0

Keywords

Search

Navigation